Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Protein molecule seems to slow progression of deadly lung disease

Protein molecule seems to slow progression of deadly lung disease

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

Boehringer announces first results of Phase III INPULSIS trials at 2014 ATS International Conference

Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with  pulmonary fibrosis

Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with pulmonary fibrosis

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Research reveals 2 key mechanisms of oxidative stress regulation

Research reveals 2 key mechanisms of oxidative stress regulation

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

Cedars-Sinai research team receives grant to develop treatment for idiopathic pulmonary fibrosis

Cedars-Sinai research team receives grant to develop treatment for idiopathic pulmonary fibrosis

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

ATS Foundation, American Lung Association to co-fund $80,000 grant to support HPS research

ATS Foundation, American Lung Association to co-fund $80,000 grant to support HPS research

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary fibrosis

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary fibrosis

6MWT wording change could enhance serial utility

6MWT wording change could enhance serial utility

Scientists transform human stem cells into functional lung and airway cells

Scientists transform human stem cells into functional lung and airway cells

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Findings demonstrate potential new therapeutic approach to treat fibrotic diseases

Findings demonstrate potential new therapeutic approach to treat fibrotic diseases

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.